Trial Profile
Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2021
Price :
$35
*
At a glance
- Drugs Methyl aminolevulinate (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Acronyms SESAME 2
- Sponsors Galderma
- 03 May 2018 New trial record